|
|
|
28.08.26 - 15:06
|
Biosergen′s Rights Issue Oversubscribed (Cision)
|
|
|
Biosergen AB (publ) ("Biosergen" or the "Company") today announces the outcome of the rights issue of shares (the "Rights Issue") for which the subscription period ended on 26 August 2026. The final outcome shows that 58,905,204 shares have been subscribed for with support of subscription rights, corresponding to approximately 73.8 percent of the offered shares. In addition, applications have been received to subscribe for 62,693,744 shares without support of subscription rights, corresponding to approximately 78.5 percent of the offered shares. The outcome shows that the Rights Issue has...
|
|
|
|
|
|
|
28.08.26 - 10:12
|
Elicera Therapeutics receives Notice of Allowance for U.S. patent application protecting the ELC-401 CAR T-cell candidate (Cision)
|
|
|
Gothenburg, August 28, 2026 – Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells armed with bystander immune activating properties using the company's commercially available platform iTANK, today announced that it has received a Notice of Allowance from the USPTO (United States Patent and Trademark Office) regarding its patent application for the CAR T-cell candidate ELC-401.
The patent application protects Elicera's special antibodies that recognize and bind to the protein...
|
|
|
28.08.26 - 08:06
|
Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2026 (Cision)
|
|
|
Second quarter (January-March 2026)
· Operating profit/loss amounted to SEK -6,305,471 (-2,892,341)
· Loss for the period amounted to SEK -6,261,763 (-2,732,070)
· Cash flow from operating activities totaled SEK -3,950,514 (-5,991,211)
· Earnings per share before and after dilution totaled SEK -0.12 (-0.06)
Period (January-June 2026)
· Operating profit/loss amounted to SEK -11,422,250 (-10,961,745)
· Loss for the period amounted to SEK -11,321,823 (-10,745,532)
· Cash flow from operating activities totaled SEK -10,932,926 (-6,736,135)
· Earnings per share...
|
|
|
27.08.26 - 18:48
|
Hansa Biopharma participating in Pareto Securities′ 17th Annual Healthcare Conference 2026 (Cision)
|
|
|
Lund, Sweden, 27 August. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will be presenting at Pareto Securities' 17th Annual Healthcare Conference 2026 in Stockholm, at 12:45-13:05 CEST, on Wednesday 2 September, as well as participating in a panel discussion later that day at 14:50-15:10 CEST.
If you are interested in meeting with Hansa's management, please contact Hansa Biopharma at ir@hansabiopharma.com.
Event: Pareto Securities' 17th Annual Healthcare Conference 2026
Date and Place: Wednesday 2 September,...
|
|
|
27.08.26 - 16:06
|
FUJIFILM Americas Welcomes Michael J. Hartman as Vice President, General Counsel and Secretary (Business Wire)
|
|
|
VALHALLA, N.Y.--(BUSINESS WIRE)--FUJIFILM Holdings America Corporation (FUJIFILM Americas) today announced the leadership appointment of Michael (Mike) J. Hartman as Vice President, General Counsel and Secretary, effective August 24. This new appointment strengthens the leadership team for FUJIFILM Americas regional headquarters, which represents more than 20 subsidiaries across the United States, Canada, Brazil, and Colombia.
“We are very pleased to welcome Mike to Fujifilm's executive leadership team,” said Kenya Nakashima, President, FUJIFILM Holdings America Corporation. “With 20-plus years of leading legal functions and teams for global healthcare and technology industry companies, Mike's depth of experience is impressive and will help guide the continued success of Fujifilm's broad and diverse businesses, as well as support our future expansion through both organic growth and acquisition.”
Most recently, Hartman served as Senior Vice President & General Counsel, Americas for Elekta, a glo...
|
|
|
27.08.26 - 15:42
|
Inify Laboratories - mandatory notification of trade (Cision)
|
|
|
Stockholm, Sweden, 27 August 2026; Inify Laboratories AB (publ.) (the "Company") announces that the following transactions have been completed by close associates of Magne Jordanger, board member and primary insider in Inify:
- Gallivant S.a.r.l, a company closely associated with board member Magne Jordanger, has sold 47,410,660 shares in Inify at an average price of NOK 7.90 per share on August 26th, 2026. After the transaction, Gallivant S.a.r.l. holds 17,167,701 shares in Inify.
- Borasco S.a.r.l., a company closely associated with board member Magne...
|
|
|
27.08.26 - 14:54
|
Glycorex Transplantation (GTAB B): Signs distribution agreement in Malaysia for Glycosorb® ABO (Cision)
|
|
|
Glycorex Transplantation AB (publ) continues its international expansion by enterering into a distribution agreement with OneMedik (M) SDN BHD, Malaysia.
OneMedik (M) SDN BHD specializes in the distribution of medical devices within plasmapheresis and has been operating in Malaysia since 2009. The company works closely with local healthcare providers to deliver critical medical technology across the region.
The agreement opens up a viable new market for Glycorex where 70% of kidney transplants are performed using living donors, an indication where Glycorex's technology is viewed as...
|
|
|
27.08.26 - 14:42
|
CHOSA Oncology accelerates value creation by entering into a commercially driven licensing agreement with Aida Oncology (Cision)
|
|
|
27 August 2026 – CHOSA Oncology AB ("CHOSA") and AIDA Oncology ApS ("AIDA"), today announces that they have entered into a strategic collaboration and global licensing agreement to bring CHOSAs Platin DRP into breast cancer. Two million new patients are diagnosed with breast cancer annually and in many cases, carboplatin may be important for cure. CHOSA is focused on lung cancer, and this paves the way for fast utilization of the Platin-DRP via AIDAs portfolio of breast cancer drug predictors.
Under the agreement, CHOSA grants AIDA rights to utilize Platin-DRP® within breast cancer, while...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
27.08.26 - 07:30
|
Interim Report second quarter 2026 (Cision)
|
|
|
NextCell Pharma AB (publ) (“NextCell” or the “Company”) publishes its Interim report for the second quarter 2026. The report is available on the company´s website: www.nextcellpharma.com. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period last year. Please note that, as of 2025, the Company's financial year corresponds to the calendar year.
Second quarter (April 1, 2026-June 30, 2026)
· Operating income SEK 3.0 million (1.5)
· Net sales SEK 3.0 million (1.5), of which Cellaviva contributed...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
